Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Financière de Tubize SA is a holding company and the reference shareholder of UCB, a leading global biopharmaceutical company based in Belgium. It owns approximately 36.27% of UCB, uniting family shareholders descended from founder Emmanuel Janssen with others sharing a long-term vision for the company's growth. The company's primary function is to support UCB's development as a committed stakeholder, fostering a rich biopharma ecosystem worldwide to enhance value creation for patients. UCB specializes in innovative treatments for neurology and immunology disorders, with key products including CIMZIA for rheumatoid arthritis and Crohn’s disease, Keppra and Vimpat for epilepsy, Zyrtec antihistamine, BIMZELX for plaque psoriasis, FINTEPLA for rare epilepsy syndromes, and RYSTIGGO and ZILBRYSQ for myasthenia gravis. Historically, Financière de Tubize has deepened its UCB stake since first investing decades ago, peaking at 40% in 2002, and participated in capital increases for acquisitions like Celltech, Schwarz Pharma, Ra Pharmaceuticals, and Zogenix. Operating in the healthcare sector with a focus on biotechnology, it plays a pivotal role in sustaining UCB's advancements in genetics, biomarkers, and human biology, primarily generating revenue in the United States followed by Europe. With around 250 employees, Financière de Tubize SA underscores stability in the biopharma investment landscape.
€215.40
+€0.80 (+0.37%)
EOD Jun 23, 2026 · Twelve Data
At 103x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Negative free cash flow of -€3M. The business is consuming cash, not generating it.
102.8x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
€93M
▲ +3.5% YoY
Op. Margin
—
ROIC
-0.16%
Cash Flow & Balance Sheet
FCF (TTM)
-€3M
▼ -62.9% YoY
Op. Cash Flow (TTM)
-€3M
▼ -62.9% YoY
Net Debt
-€1M
Net Cash Position
Cash & Equiv.
€1M
Continue Research
At a P/E of 102.8, Financière de Tubize SA (TUB.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Financière de Tubize SA scores 22/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.5%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Financière de Tubize SA scores 22 out of 100 on Intrinsiqq's quality score, passing 2 of 5 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -0.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, Financière de Tubize SA pays a regular dividend of about €1.04 per share per year (typically in quarterly installments), a yield of roughly 0.5% at the current price. That is a payout ratio of about 49.7% of earnings, so the dividend is well covered. Financière de Tubize SA has grown the dividend at roughly 11.2% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For TUB.XBRU's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. you should weigh TUB.XBRU's valuation and scores 22/100 on quality (lower-quality). It also yields about 0.5%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.